Hypertrophic cardiomyopathy (HCM) presents multiple challenges in the diagnosis, prognosis, and treatment of patients with this disease. In this series, recent evidence and insights will be unraveled on the epidemiology, clinical features, pathophysiology, and new treatment options in HCM. Moreover, two experts break down the recommendations for management of HCM in the transatlantic guidelines.
This course consists of 4 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and MEDCON International. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until July 18, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .75 contact hour/0.075 CEUs of pharmacy contact hours. The Universal Activity Number for this program is JA0006235-0000-24-082-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 40 minutes of effective education time.